BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, February 10, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 26, 2010
View Archived Issues
Memory Pharmaceuticals claims novel 5-HT6 receptor ligands
Read More
Triad Multitech claims new nitrogen- and sulfur-containing agents
Read More
TransTech Pharma patents novel modulators of the AgRP-MC4 receptor interaction
Read More
New butyrylcholinesterase ligands claimed by Treventis as diagnostic agents
Read More
Galderma discovers novel LXRbeta ligands
Read More
Merck and Ligand identify new beta-secretase 1 inhibitors with potential in Alzheimer's disease
Read More
ASPIRE study finds no benefit of add-on aliskiren on end systolic volume after myocardial infarction
Read More
PERSEUS data support efficacy of Taxus Element paclitaxel-eluting stent
Read More
Preclinical data disclosed on S1P1 receptor agonist PF-991 for treatment of autoimmune disorders
Read More
European Commission approves DuoPlavin/DuoCover dual antiplatelet combination tablet
Read More
Merck Serono temporarily suspends worldwide clinical development program of Stimuvax
Read More
Santarus completes enrollment in second U.S. phase III trial of budesonide in ulcerative colitis
Read More
Penn Medicine and AstraZeneca collaborate to discover new Alzheimer's disease therapeutics
Read More
Tysabri enters head-to-head phase III trial for multiple sclerosis
Read More
Preclinical data on novel orally active FXa inhibitor TAK-442 presented at ACS Meeting
Read More
Shire presents data from patients with Gaucher's disease who switched to VPRIV
Read More
Dara BioSciences begins phase I trial of DB-959 in type 2 diabetes
Read More
Takeda submits application in Japan for additional indications for alogliptin
Read More
EyeGate Pharma completes phase II EGP-437 study in uveitis
Read More
Health Canada approves Avastin for glioblastoma multiforme
Read More
CryoLife withdraws proposal to acquire Medafor
Read More
Transcept updates plan for Intermezzo NDA resubmission
Read More
Portola begins phase I trial of oral SYK inhibitor PRT-062607 for inflammatory disease and cancer
Read More
Bionomics to initiate second phase II trial of BNC-105 for advanced mesothelioma
Read More
DMC recommends continued enrollment in eritoran phase III trial for severe sepsis
Read More
